With the growing demand for integrated safety and compliance solutions, our toxicological interpretation alongside our testing and investigation services delivers a holistic approach to pharmaceutical product safety and regulatory compliance.
From assessing new active pharmaceutical ingredients (APIs) and excipients, impurities and residual solvents to evaluating contaminants through extractables and leachables (E&L) hazard screening and full assessments. We support clients with toxicology data strategies and dossier preparation, ensuring robust and reliable risk assessments.
We provide expert evaluations of health risks associated with various substances, contaminants, and materials, bespoke to your product using desk-based (encompassing literature, threshold techniques (TTC), read across amongst other techniques) , tailored risk assessments.
Delivered by our expert team using established models and published, peer reviewed literature, we will support you with an array of services including the following:
Our services are crucial at various stages of pharmaceutical product development ensuring regulatory compliance and safety. During product development, we perform risk assessments on new APIs, excipients, and novel technologies which provide key information, equipping clients to make decisions which aid safety throughout the product lifecycle.
Additionally, our expertise in investigations and R&D allows us to react promptly to product defects, contaminations, and potential recalls.
The toxicological methods adopted by RSSL offer several benefits including tailored project and risk assessments aligned with the clients required legislative framework, along with rapid desk-based screening of large libraries of compounds due to our high-throughput capabilities.
In Silico toxicology modelling approaches such as QSAR, are also increasingly recognised as a valuable compliment to traditional testing methods, our experts identify the right modelling tool for assessments, reducing the need for extensive investigations and thus cost and time.
With current regulatory and public demand for humane alternatives to animal testing, In Silico methods consider ethical factors by reducing this requirement.